Fecal transplants could ward off depression. Researchers have a pill for that

By Bill Kaufmann

Published Aug 13, 2024

What might seem stomach-turning could prove a key to better mental health, say University of Calgary researchers.

The scientists have embarked on a study to determine if fecal microbiota transplant (FMT) using so-called poop pills can reduce the effects of depression and obsessive-compulsive disorder (OCD).

In a U of C lab, technicians on Tuesday prepared a brown liquid in a kitchen mixer, then squeezed the substance into white and blue capsules that’ll be served to study participants that researchers are seeking to recruit.

“Our gut bugs are part of us — they help us sleep, digest food and provide us with vitamins, and seem to have a connection with how our brains work,” said Dr. Thomas Louie, a clinical medicine professor who’s been working with FMT, particularly in treating C. difficile infections, the most common hospital-borne illness.

Early studies suggest altering the microbiome in the stomach can improve signaling between the gut and the brain, said Louie and study leader Dr. Valerie Taylor.

Share the Post:
Receive the latest news

Join Our Journey

Be the First to Know: Unlock exclusive updates on the progress and launch timeline of our groundbreaking biotherapeutics product development.

Name(Required)

Asem Bala

MSc

Asem Bala, MSc has over 20 years of experience in Healthcare & Clinical Research Management, now working at Taylored Biotherapeutics to create partnerships and ensure regulatory approvals.

Dr. Valerie Taylor

MD, PhD, FRCP

Dr. Valerie Taylor, MD, PhD, FRCP is a Professor of Psychiatry at the University of Calgary. She completed a Bachelor of Medical Science and graduated from medical school at Memorial University of Newfoundland. She subsequently finished her residency training in Psychiatry and got her PhD in Neuroscience from McMaster University in Hamilton, Ontario. Prior to coming to Calgary, she was the chief of Psychiatry at the Women’s College Hospital and the chief of Adult Health Services at the Center for Addiction and Mental Health in Toronto.

Her academic focus has been on the area of medical psychiatry – specifically, for the last 5 years, on the gut brain axis and the the gut microbiome. She is the only funded researcher in North America examining the therapeutic effects of fecal transplant as a treatment for mental health and she currently has 4 novel clinical trials looking at modifying the gut microbiome to treat mood disorders as well as the largest biological neuroscience microbiome repository in North America. She has over 180 peer reviewed publications and funding from a variety of national and international funding agencies. In 2020 she started Taylored Biotherapeutics, a micro therapeutics drug company. Today her primary role is in leading product development, getting regulatory approval, and finding partnerships.